Tumor reversion holds promise

Tumor reversion holds promise

In the present issue of the journal, Makoto Noda and colleagues present a screening assay for anti-cancer drugs based on tumor reversion, identifying a series of hitherto unsuspected compounds that are of potential therapeutic interest. More specifically, the assay is based upon triggering the promoter of Reck, which functions as an inhibitor of metalloproteinases. Among the pharmaceutical agen...

The piggyBac transposon holds promise for human gene therapy.

E ver since their molecular isolation in eukaryotic organisms, transposons have been precious implements of the geneticist’s toolkit. The properties that make transposons so useful are their ability to move from one chromosomal position to another and the relatively minimal requirements for transposition to occur in the test tube and in living cells (1). In particular, transposons can be harnes...

MEK inhibition holds promise for polycystic kidney disease.

P olycystic kidney disease (PKD) has a number of characteristics that make it uniquely challenging for the development of therapies to slow disease progression. Renal cystic diseases result from the neoplastic growth of numerous fluid-filled cysts, often accompanied by increased apoptosis, tissue remodeling, inflammation, and fibrosis (1–3). The slow, inexorable growth of these renal cysts, par...

Polypill holds promise for people with chronic disease.

News Polypill holds promise for people with chronic disease Efforts are under way to make medicines for chronic diseases more accessible to people in developing countries. A " polypill " containing a fixed-dose of aspirin, a statin and one or two blood-pressure-lowering drugs, has enormous potential in developing countries, where the rate of cardiovascular disease is rising rapidly, according t...

New technology holds promise 1 New technology holds promise for the future application of psychophysiological methods for the enhancement of performance during sport and exercise